PsyTech

Dedicated to driving psychedelic research, education and innovation forward. 

OUR MISSION

We are dedicated to driving psychedelics forward, by building a robust and all-encompassing community and directly advancing promising ventures in psychedelics.

WHY US?

PsyTech was incubated by iCAN (Israel-cannabis) and developed by the team behind Cannatech, the premiere international cannabis summit. Leveraging the highly relevant experience of iCAN, PsyTech is positioned to lead the global psychedelic conversation forward.

WHY NOW?

In 1971 psychedelics were classified as a Schedule I drug in the United States, shutting down all of the promising research that had been conducted since the late 1940’s. Recently, psychedelics have re-emerged and are experiencing a radical renaissance as their potential to treat a wide variety of health conditions is being recognized. Today, patients, physicians and research scientists are expressing an urgency in accelerating psychedelic medicine to its’ full potential. It is this urgency that inspired the creation of PsyTech.

HOW DO WE DRIVE INNOVATION?

We drive psychedelics forward by building community in a wide range of sectors, including clinical research/ biochemistry, patient advocacy, regulatory and public policy, investment and business development as well as advancing ventures in this burgeoning industry . 

In service to our mission, PsyTech operates two branches:

CONNECT

Our live global summits, virtual events and online community resources are designed to build a psychedelic movement and push good research, compassionate public policy and responsible business forward.

DISCOVERY

Leveraging the PsyTech community, we will directly advance promising ventures in psychedelics.

 

What the experts say about psychedelics

Stay updated

Sign up for our newsletter and tell us about your interest in psychedelic medicines.